NCT04566900 is a NA clinical trial of Neurofeedback in Mild Cognitive Impairment, sponsored by University of California, San Diego.

Who is sponsoring NCT04566900?

NCT04566900 is sponsored by University of California, San Diego.

What drugs are being tested in NCT04566900?

Interventions in NCT04566900: Neurofeedback, Placebo.

What condition does NCT04566900 study?

NCT04566900 studies Mild Cognitive Impairment.

Is NCT04566900 still recruiting?

NCT04566900 is currently active, enrolled. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT04566900

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurofeedback to Improve Working Memory in Mild Cognitive Impairment

Active, enrolled NA Last updated 27 January 2026

What this trial tests

NA trial testing Neurofeedback in Mild Cognitive Impairment in 112 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2021

Primary endpoint
30 April 2026

31 July 2026

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	112
Start date	1 January 2021
Primary completion	30 April 2026
Estimated completion	31 July 2026
Sites	1 location across United States

Drugs / interventions tested

Neurofeedback
Placebo

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

University of California, San Diego

Who can join

Adults 50 to 85, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mild cognitive impairment (MCI) has been identified as an early phase of Alzheimer's disease (AD), a neurodegenerative disorder expected to affect 13.9 million Americans by 2060. AD causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality. Treatment intervention at the MCI stage of the disease could potentially slow down the rate at which people may convert from MCI to AD. Increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in AD. Furthermore, previous research has shown that neurofeedback (NFB) training targeting these regions can improve memory, making it a potential treatment for AD. NFB is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor. We are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with MCI. Results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with MCI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neurofeedback

Trials testing the same drug.

NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT06587919 — Improving Dysregulated Neural Networks With EEG-neurofeedback · NA · enrolling by invitation
NCT06240299 — Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) · NA · recruiting
NCT06188910 — Neurofeedback and Nomophobia in Young Adults · NA · completed
NCT06557525 — Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER) · Phase 1, PHASE2 · recruiting

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04566900 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing